trial

A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

NCTId NCT01617187
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 360 (actual)
Sponsored by Organon and Co
Primary completion 2014-08-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
360 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2012-12-04
Primary completion
2014-08-11
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AsenapineOlanzapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Ex — primary completion2014-08-11

Facts & assertions

4 sourced
Enrollment
360
Phase
PHASE3
Primary Completion Date
2014-08-11
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
Olanzapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication